Lazard Asset Management
ARCT icon

Lazard Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Lazard Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,104
Closed -$275K – 2290
2025
Q1 		$275K Buy
26,104
+19,414
+290% +$308K ﹤0.01% 1556
2024
Q4 		$112K Sell
6,690
-2,299
-26% -$43.3K ﹤0.01% 1767
2024
Q3 		$207K Buy
8,989
+39
+0.4% +$834 ﹤0.01% 1598
2024
Q2 		$216K Sell
8,950
-10,489
-54% -$318K ﹤0.01% 1530
2024
Q1 		$655K Sell
19,439
-8,439
-30% -$299K ﹤0.01% 1004
2023
Q4 		$877K Buy
27,878
+18,161
+187% +$432K ﹤0.01% 977
2023
Q3 		$247K Sell
9,717
-2,217
-19% -$68.3K ﹤0.01% 1311
2023
Q2 		$341K Buy
11,934
+2,632
+28% +$71.6K ﹤0.01% 1204
2023
Q1 		$222K Buy
9,302
+987
+12% +$17.7K ﹤0.01% 1280
2022
Q4 		$140K Sell
8,315
-666
-7% -$11.6K ﹤0.01% 1392
2022
Q3 		$133K Buy
+8,981
New +$151K ﹤0.01% 1364

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Lazard Asset Management's ARCT Position: Q2 2025 in Review

Lazard Asset Management sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 26,104 shares — an estimated $275K sold.

Lazard Asset Management first reported a position in ARCT in Q3 2022 and held it in 11 quarters. The position peaked at $877K in Q4 2023. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Lazard Asset Management reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 26,104 Arcturus Therapeutics shares in Q2 2025, an estimated $275K.
  • Lazard Asset Management first reported a position in Arcturus Therapeutics in Q3 2022 and held it in 11 quarters.
  • Lazard Asset Management's Arcturus Therapeutics position peaked at $877K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.